Can Fite Biofarma (STU:CF5) Days Payable : 0.00 (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Can Fite Biofarma Days Payable?

Can Fite Biofarma's average Accounts Payable for the three months ended in Dec. 2023 was €0.50 Mil. Can Fite Biofarma's Cost of Goods Sold for the three months ended in Dec. 2023 was €0.00 Mil.

The historical rank and industry rank for Can Fite Biofarma's Days Payable or its related term are showing as below:

STU:CF5's Days Payable is not ranked ^*
in the Biotechnology industry.
Industry Median: 151.69
* Ranked among companies with meaningful Days Payable only.

Can Fite Biofarma's Days Payable stayed the same from Dec. 2022 (0.00) to Dec. 2023 (0.00). stayed the same

Can Fite Biofarma Days Payable Historical Data

The historical data trend for Can Fite Biofarma's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Can Fite Biofarma Days Payable Chart

Can Fite Biofarma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Payable

Get a 7-Day Free Trial

Can Fite Biofarma Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Days Payable	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Can Fite Biofarma's Days Payable

For the Biotechnology subindustry, Can Fite Biofarma's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Can Fite Biofarma's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Can Fite Biofarma's Days Payable distribution charts can be found below:

* The bar in red indicates where Can Fite Biofarma's Days Payable falls into.

Can Fite Biofarma Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Can Fite Biofarma's Days Payable for the fiscal year that ended in Dec. 2023 is calculated as

	Days Payable (A: Dec. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2022 )	+	Accounts Payable (A: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2023 )	*	Days in Period
=	( (0.846	+	0.392)	/	2 )	/	0	*	365
=	0.619					/	0	*	365
=	N/A

Can Fite Biofarma's Days Payable for the quarter that ended in Dec. 2023 is calculated as:

	Days Payable (Q: Dec. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Sep. 2023 )	+	Accounts Payable (Q: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (Q: Dec. 2023 )	*	Days in Period
=	( (0.606	+	0.392)	/	2 )	/	0	*	365 / 4
=	0.499					/	0	*	365 / 4
=	N/A

Can Fite Biofarma Days Payable Related Terms

Thank you for viewing the detailed overview of Can Fite Biofarma's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Can Fite Biofarma (STU:CF5) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Can Fite Biofarma Ltd (STU:CF5) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

CANF:USA CANF:Israel

Address

10 Bareket Street, Kiryat Matalon, P.O. Box 7537, Petah-Tikva, ISR, 4951778

Website

http://www.canfite.com

Can Fite Biofarma Ltd is an advanced clinical stage drug development company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, liver, and inflammatory disease. The company's lead drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the most common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).

Can Fite Biofarma (STU:CF5) Headlines

No Headlines